Analysts Set Expectations for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Kura Oncology in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will earn ($2.94) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01. During the same period last year, the firm posted ($0.50) earnings per share.

A number of other research firms have also recently commented on KURA. Wedbush reiterated an "outperform" rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. Stifel Nicolaus lowered shares of Kura Oncology from a "buy" rating to a "hold" rating and dropped their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. HC Wainwright raised their target price on Kura Oncology from $32.00 to $37.00 and gave the stock a "buy" rating in a research note on Thursday, November 21st. Bank of America dropped their price target on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, November 22nd. Finally, UBS Group began coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus price target of $27.38.

Kura Oncology Stock Up 4.3 %

Shares of KURA stock traded up $0.32 during trading hours on Wednesday, reaching $7.71. 581,707 shares of the company's stock were exchanged, compared to its average volume of 1,443,987. Kura Oncology has a 1 year low of $6.98 and a 1 year high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $599.53 million, a PE ratio of -3.27 and a beta of 0.81. The stock's fifty day moving average price is $10.08 and its two-hundred day moving average price is $16.15.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds have recently modified their holdings of KURA. SG Americas Securities LLC purchased a new position in Kura Oncology during the fourth quarter worth approximately $436,000. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. JPMorgan Chase & Co. raised its position in Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after acquiring an additional 3,092 shares during the period. Franklin Resources Inc. lifted its holdings in Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after purchasing an additional 23,113 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after purchasing an additional 41,535 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.